trending Market Intelligence /marketintelligence/en/news-insights/trending/RpEI5mgm-vytwtQKfJDHLQ2 content esgSubNav
In This List

Mylan launches generic version of Novartis Paget's disease drug

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Mylan launches generic version of Novartis Paget's disease drug

Mylan NV launched Zoledronic acid injection in the U.S., a generic version of Novartis AG's Reclast injection.

The company received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for the product, which is indicated for the treatment of Paget's disease of bone in men and women.

According to QuintilesIMS Health data, Zoledronic acid injection in 5 milligram/100 milliliters single-dose vial had U.S. sales of about $22.1 million for the 12 months ending March 31.